2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Cancer Drug Targets
Cancer drug targets are specific molecules or pathways within cancer cells that scientists aim to inhibit or modify to prevent tumor growth or induce cancer cell death. These targets can vary widely depending on the type of cancer and its genetic makeup. Common targets include proteins involved in cell division, growth factor receptors, and enzymes that support tumor survival. Advances in genomic analysis have led to the identification of new drug targets, allowing for more precise and personalized cancer treatment strategies. Immunotherapy, for example, targets the immune checkpoint proteins that cancer cells exploit to evade detection by the immune system. By understanding and effectively targeting these key molecules, researchers are developing increasingly effective and less toxic treatments for various types of cancer.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China